

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Acute Coronary Syndromes

2 List of modelling questions

Review question by scope area	Which dual-antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI or for managing STEMI in adults?
Population	People with STEMI and UA/NSTEMI undergoing PCI
Interventions and comparators considered for inclusion	<ul style="list-style-type: none"> • Clopidogrel (plus aspirin) • Prasugrel (plus aspirin) • Ticagrelor (plus aspirin)
Perspective	Interventions with health outcomes in the NHS setting (UK NHS and PSS costs)
Outcomes	Cost per QALY gained
Type of analysis	Cost-utility analysis (decision tree and Markov model; lifetime horizon)
Issues to note	STEMI and UA/NSTEMI were analysed as separate populations in the cost-effectiveness analysis due to potential differences in baseline risks.